Micro‐Engineered Organoid‐on‐a‐Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients

Micro‐Engineered Organoid‐on‐a‐Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients

Abstract Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide. Patient‐derived organoid (PDO) has great potential in precision oncology, but low success rate, time‐consuming culture, and lack of tumor microenvironment (TME) limit its application. Mesenchymal stromal cells (MSC)...

Full description

Bibliographic Details
Main Authors: Zhengyu Zou, Zhun Lin, Chenglin Wu, Jizhou Tan, Jie Zhang, Yanwen Peng, Kunsong Zhang, Jiaping Li, Minhao Wu, Yuanqing Zhang
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:Advanced Science
Subjects:
cancer immunotherapy
drug screening
mesenchymal stromal cells
microfluidics
tumor organoids
Online Access:https://doi.org/10.1002/advs.202302640

Internet

https://doi.org/10.1002/advs.202302640

Similar Items